title: Feeding responses to a melanocortin agonist and antagonist in obesity induced by a palatable high-fat diet.
abstract: Hypothalamic melanocortins are critical for the control of food intake, and alterations in POMC mRNA have been described in genetic models of obesity. However, the time course of changes in brain transmitters over the development of dietary obesity is less clear. Therefore, we examined the effect of diet-induced obesity on hypothalamic alpha-MSH content and feeding responsiveness to synthetic melanocortins. Male Sprague-Dawley rats fed a high-fat cafeteria diet (30% fat) or chow (5% fat) for 4 or 12 weeks were implanted with intracerebroventricular cannulae and feeding responses to the MC3/4R agonist MTII (0.5 nmol) and the selective MC4R antagonist HS014 (0.8 nmol) were determined. MTII had a long-lasting inhibitory effect on food intake. Chronically overfed animals had a significantly exaggerated inhibitory feeding response 15 and 24 h after MTII injection and lost more body weight (15 +/- 3 g) compared to control rats (4 +/- 4 g; P < 0.05). Daytime administration of HS014 significantly increased food intake in all rats to the same extent (P < 0.05). No change in hypothalamic alpha-MSH content was observed after 2 or 12 weeks of high-fat diet. The observation of increased responsiveness to the melanocortin agonist, in the face of a high-fat diet, suggests melanocortin analogues may have potential for the pharmacological treatment of obesity.
authors.affiliation: Neuroendocrine Laboratory, Department of Pharmacology, The University of Melbourne, Victoria 3010, Australia.
authors.forename: Michelle J
authors.initials: MJ
authors.lastname: Hansen
authors.forename: Helgi B
authors.initials: HB
authors.lastname: Schiöth
authors.forename: Margaret J
authors.initials: MJ
authors.lastname: Morris
mesh_terms: D000818:Animals; D004041:Dietary Fats / Q000378:metabolism*; D004195:Disease Models, Animal; D004435:Eating / Q000187:drug effects / Q000502:physiology; D007031:Hypothalamus / Q000187:drug effects / Q000378:metabolism; D007276:Injections, Intraventricular; D020738:Leptin / Q000097:blood; D008297:Male; D009765:Obesity / Q000097:blood / Q000378:metabolism*; D044343:Overnutrition / Q000378:metabolism; D010456:Peptides, Cyclic / Q000008:administration & dosage*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044101:Receptors, Melanocortin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000187:drug effects*; D013997:Time Factors; D000521:alpha-MSH / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000187:drug effects / Q000378:metabolism*
chemical_list: D004041:Dietary Fats; C116941:HS014 cyclic peptide; D020738:Leptin; D010456:Peptides, Cyclic; D044101:Receptors, Melanocortin; C081720:alpha-MSH (4-10)amide, Ac-Nle(4)-cyclo(Asp(5)-Phe(7)-Lys(10))-; D000521:alpha-MSH